INDV:NASDAQIndivior Pharmaceuticals, Inc. Analysis

Indivior posted a robust Q1‑26 performance, with total net revenue of $317 million up 19% YoY and SUBLOCADE sales climbing 32% to $232 million. Operating margins remain exceptionally high at 46% and gross margins near 85%, supporting a record adjusted EBITDA of $164 million, more than double the prior year. The company’s forward EPS of $3.97 translates to a forward P/E of roughly 9.6, well below the industry average of 24, indicating strong earnings growth potential. However, the discounted cash flow model values the stock at only about $8 per share, implying the current market price of $38.30 is significantly overvalued. Technicals are bullish – the price sits above the 20‑day, 50‑day and 200‑day SMAs, MACD is in a bullish crossover, and RSI is at a moderate 58, while volume remains stable. Extreme greed sentiment (Fear & Greed Index 91.46) and a 32% upside/downside metric suggest market enthusiasm, yet the high 30‑day volatility (32%) and a beta under 1 signal notable price swings. The recent $125 million share repurchase (≈4 million shares) may provide short‑term support but does not resolve the valuation gap. Overall, INDV combines strong growth fundamentals with an overextended price, making it a candidate for cautious positioning.